Drugs / OSE-279
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05751798 | Dec 2022 → Dec 2029 expected | lymphoma, non-small cell lung carcinoma | OSE Immunotherapeutics | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | OSE-279 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05751798 ↗ |
| Action | Inhibit | “PD-1 blocking monoclonal antibody” NCT05751798 ↗ |
| Modality | Monoclonal antibody | “OSE-279, a PD-1 blocking monoclonal antibody” NCT05751798 ↗ |
| Route | Intravenous | “single IV infusion” NCT05751798 ↗ |